New Method To Produce Blood Cells From Stem Cells Could Yield A Purer, Safer Cell Therapy
Jul 17th, 2013 · Comments Off
Main Category: Stem Cell Research
Also Included In: Blood / Hematology
Article Date: 16 Jul 2013 – 2:00 PDT
As such, it could lead to a purer, safer therapeutic grade of stem cells for use in regenerative medicine.
All opinions are moderated before being included (to stop spam)
Current ratings for:
New Method To Produce Blood Cells From Stem Cells Could Yield A Purer, Safer Cell Therapy
STEM CELLS Translational Medicine
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
Contact Our News Editors
The discovery of iPSCs holds great promise for regenerative medicine since it is possible to produce patient-specific iPSCs from the individual for potential autologous treatment – that is, treatment using the patient’s own cells. This avoids the possibility of rejection and numerous other harmful side effects.
CD34+ cells are a type of blood stem cell that has been linked to proliferation. However, collecting enough CD34+ cells from a patient to produce an adequate amount of blood usually requires a large volume of blood to be taken from the patient. But scientists found a way around this, as outlined in the new study conducted by researchers in the Department of Medicine and Institute for Human Genetic, University of California-San Francisco. They were led by Yuet Wai Kan, M.D., FRS, and Lin Ye, Ph.D.
stem cell research section for the latest news on this subject.
Blood cell derived induced pluripotent stem cells free of reprogramming factors generated by Sendai viral vectors, Lin Ye, Marcus O. Muench, Noemi Fusaki, Ashley I. Beyer, Jiaming Wang, Zhongxia Qi, Jingwei Yu and Yuet Wai Kan, First Published Online July 11, 2013, Stem Cells Translational Medicine, doi: 10.5966/sctm.2013-0006
Please note: If no author information is provided, the source is cited instead.
Please use one of the following formats to cite this article in your essay, paper or report:
MLA
“We used Sendai viral vectors to generate iPSCs efficiently from adult mobilized CD34+ and peripheral blood mononuclear cells (MNCs),” Dr. Kan explained. “Sendai virus is an RNA virus that carries no risk of altering the host genome, so is considered an efficient solution for generating safe iPSC.”
APA
For any corrections of factual information, or to contact the editors please use our feedback form.
Please send any medical news or health news press releases to:
privacy policy for more information.
“Just 2 milliliters of blood yielded iPS cells from which hematopoietic stem and progenitor cells could be generated. These cells could contain up to 40 percent CD34+ cells, of which approximately 25 percent were the type of precursors that could be differentiated into mature blood cells. These interesting findings reveal a protocol for the generation iPSCs using a readily available cell type,” Dr. Ye added. “We also found that MNCs can be efficiently reprogrammed into iPSCs as readily as CD34+ cells. Furthermore, these MNCs derived iPSCs can be terminally differentiated into mature blood cells.”
STEM CELLS Translational Medicine. “New Method To Produce Blood Cells From Stem Cells Could Yield A Purer, Safer Cell Therapy.” Medical News Today. MediLexicon, Intl., 16 Jul. 2013. Web.
16 Jul. 2013. <http://www.medicalnewstoday.com/releases/263386.php>
